This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
8/15/2022
The conference will begin shortly. To raise your hand during Q&A, you can dial star 1-1. Good day and thank you for standing by.
Welcome to the Alano's Therapeutic second quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1-1 on your telephone. Please, the advice of today's conference may be recorded. I would like to hand the conference over to your speaker today, Danielle Dudgeon, with Stern Investor Relations. Please go ahead.
Good morning, and welcome to the Alana Therapeutics Second Quarter 2022 Financial Results Conference Call and Audio Webcast. With me today are Kevin Boyle Sr., Chief Executive Officer, Drew Deniger, Vice President of Research and Development, Abhisek Srivastava, Vice President of Technical Operations, and Mike Wong, Vice President of Finance. Earlier this morning, ALONOS issued a press release announcing financial results the three months ended June 30th, 2022. We encourage everyone to read today's press release as well as the ALONOS quarterly report on Form 10-Q for the quarter ended June 30th, 2022, which was filed this morning with the SEC. The company's press release and quarterly report will also be available on the Alanos website at alanos.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information, that is accurate only as of the date of this live broadcast, August 15, 2022. Actual results could differ materially from those stated or implied by the forward-looking statements made today due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law. With that said, I would like to turn the call over to Kevin Boyle.
You're reading a preview of the TCRT Q2 2022 earnings call.
Free account.
